Economic evaluation of Nootropil® in the treatment of acute stroke in France

Pharmacological Research

Volumn 36, Issue 5, 1997, Pages 373-380

  Murphy, N ^a   Kazek, M P ^a   Van Vleymen, B ^a   Melac, M ^a   Souetre E ^a  

^a Benefit International SNC   (France)

Author keywords

Cost effectiveness; Ischaemic stroke; Piracetam

Indexed keywords

NOOTROPIC AGENT; PIRACETAM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; FRANCE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INSTITUTIONALIZATION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STROKE; TIME;

EID: 0031280489     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0244     Document Type: Article

References (27)

1. 1. Hopkins A. Clinical Neurology; A Modern Approach; Chap. 10: Ed Oxford Univerity Press, 1993.
2. 2. Dunbabin M. Cost-effective intervention in stroke. Pharmacoeconomics 1992; 2(6): 468-99.
3. 3. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community stroke project - 1981-86, 2. J Neurol Neurosurg Psychiatry 1990; 53(1): 16-22.
4. 4. Sacco RL, Hauser WA, Mohr JP, Foulkes MA. One-year outcome after cerebral infarction in Whites, Blacks and hispanics. Stroke 1992; 22(3): 305-11.
5. 5. Mitchell J, Ballard D, Whisnant J, Matchar D. What role do neurologists play in determining the costs and outcome of stroke patients. Stroke 1996; 27: 1937-43.
6. 6. Giurgea C, Mouravieff-Lesuisse F, Leemans R. Correlations électro-pharmacologiques au cours de l'anoxie oxyprive chez le lapin en respiration libre ou artificielle. Rev Neurol (Paris) 1970; 122: 484-6.
7. 31P nuclear magnetic resonance and conformational analysis. Biochem Pharmacol 1995; 50: 1129-34.
8. 8. Müller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 1997; 53: 135-40.
9. 9. Benzi G, Pastoris O, Villa RF, Gruffrida RM. Influence of aging and exogenous substances on cerebral energy metabolism in post-hypoglycemic recovery. Biochem Pharmacol 1985; 34: 1477-83.
10. 3H-glutamate sites. Arzneimittelforschung 1985; 35: 1350-2.
11. 11. Nickolson VJ, Wolthuis OL. Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and metamphetamine. Biochem Pharmacol 1976; 25: 2241-4.
12. 12. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 1993; 43: 301-5.
13. 13. Rosenhall U, Deberdt W, Frieberg U, Kerr A, Oosterveld W. Piracetam in patients with chronic vertigo: results of a double-blind, placebo-controlled study. Clin Drug Invest 1996; 11(5): 251-60.
14. 14. Brown P, Steiger MJ, Thompson PD, Rothwell JC, Day BL, Salina M, Waegemans T, Marsden CD. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993; 8: 63-8.
15. 15. Enderby P, Broeckx J, Hospers W, Schildermans F, Deberdt W. Effect of piracetam on recovery and rehabilitation after stroke. A double-blind, placebo-controlled study. Clin Neuropharmacol 1994; 17: 320-31.
16. 16. Huber W, Willmes K, Poeck K, Van Vleymen B, Deberdt W. Piracetam as an adjuvant to language therapy for aphasia: a randomised double-blind placebo-controlled pilot study. Arch Phys Med Rehabil 1997; 78: 245-50.
17. 17. Clinical report PASS. The Piracetam Acute Stroke Study Group: Piracetam versus placebo in the acute treatment of aute ischaemic supratentorial cerebrovascular accidents: a double blind, randomised, multicenter study. UCB internal report 1997; MRCE96M1201.
18. 18. Carnets statistiques 1995. Le secteur libéral de professions de santé en 1994, C.N.A.M.T.S.
19. 19. 'Nomenclature des actes professionnels' (updated in 1995).
20. 20. Carnets statistiques 1995. 'Le régime général en 1994, C.N.A.M.T.S.
21. 21. Accesoirex 1995; Eds Société d'éditions medico -pharmaceutiques.
22. 22. Drummond MF, Ward GH. The financial burden of stroke and the economic evaluation of treatment alternatives. In: Rose FC, ed. Stroke: Epidemiological, Therapeutic and Socioeconomic Aspects. London, England: Royal Society of Medicine Services Ltd, 1987.
23. 23. Terent A. Medico-social consequences and direct costs of stroke in a Sweedish community. Scand J Rehabil Med 1983; 15: 165-71.
24. 24. Mills E, Thompson M. The economic costs of stroke in Massachusetts. N Engl J Med 1978; 299: 415-18.
25. 25. Isard PA, Forbes JF. The cost of stroke to the National Health Service in Scotland. Cerebrovasc Dis 1992; 2: 47-50.
26. 26. Smurawska LT, Alexandrov AV, Bladin CF, Norris JW. Cost of acute stroke care in Toronto, Canada. Stroke 1994; 25: 1628-31.
27. 27. Bergman L, Van der Meulen JHP, Limburg M, Habbema DF. Cost of medical care after first-ever stroke in the Netherlands. Stroke 1995; 26: 1830-6.